Australian Clinical Labs Limited
Australian Clinical Labs Limited
Your view on ACL.AX
Overview
What the company does, where it operates, and who runs it.
About Australian Clinical Labs Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Melinda McGrath
- Headquarters
- 1868-1892 Dandenong Road, Clayton, VIC, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Melinda McGrath
- Headquarters
- 1868-1892 Dandenong Road, Clayton, VIC, AU
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Australian Clinical Labs Limited, and the rating behind it. ACL.AX last traded at AUD 2.38, 23.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Australian Clinical Labs Limited. Starting points for Australian Clinical Labs Limited: P/E 23.7, EPS AUD 0.12, beta 0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Australian Clinical Labs Limited. Australian Clinical Labs Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Australian Clinical Labs Limited. Trailing twelve-month EPS for Australian Clinical Labs Limited stands at AUD 0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Australian Clinical Labs Limited. Australian Clinical Labs Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Australian Clinical Labs Limited valued side by side against its closest peers. Australian Clinical Labs Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Australian Clinical Labs Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Australian Clinical Labs Limited executives and directors. Shares of Australian Clinical Labs Limited have traded between AUD 1.83 and AUD 2.97 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Australian Clinical Labs Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Australian Clinical Labs Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Australian Clinical Labs Limited. Coverage tracks Australian Clinical Labs Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.